106128-89-6
基本信息
succinyl(asp6
Senktide?, BR
SENKTIDE (6-11)
SUC-DF(ME)FGLM-NH2
SUC-DF-(NMEF)-GLM-NH2
M.W. 842.1 C40H55N7O11S
Senktide trifluoroacetate salt
Suc-[Asp6,MePhe8]substance P(6-11)
[SUCCINYL-ASP6,ME-PHE8] SUBSTANCE P
物理化學(xué)性質(zhì)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-P0187 | SUCCINYL-ASP-PHE-ME-PHE-GLY-LEU-MET-NH2 Senktide | 106128-89-6 | 1mg | 700元 |
2024/11/08 | HY-P0187 | SUCCINYL-ASP-PHE-ME-PHE-GLY-LEU-MET-NH2 Senktide | 106128-89-6 | 5mg | 1600元 |
2024/11/08 | HY-P0187 | SUCCINYL-ASP-PHE-ME-PHE-GLY-LEU-MET-NH2 Senktide | 106128-89-6 | 10mg | 2488元 |
常見問題列表
NK 3 receptor
The selective NK 3 receptor agonist Senktide excites 24 of 31 dopaminergic neurons in the substantia nigra pars compacta in a concentration-dependent manner. The effective concentration range is between 3 to 3000 nm. The mean EC 50 for Senktide is 41.2±9 nm (n=5).
I.c.v. injection of Senktide causes a dose-dependent increase in total distance traveled (F 6,72 =6.344, P<0.001). This increase reaches statistical significance compare to the vehicle-treated group at 0.06 nmol and higher. The Senktide-induced increase in locomotor activity brought about by 0.1 nmol of Senktide is significantly and dose-dependently decreased by the tachykinin NK 3 receptor antagonists talnetant at 30 mg/kg and SB222200 at 30 mg/kg, but not by osanetant, when tested in parallel in a single experiment (F 7,78 =10.32, P<0.001), although a non-significant reduction is observed. However, when tested using another vehicle (Vitamin E and glycofurol), osanetant does decrease activity significantly compare to Senktide-treated gerbils (F 2,30 =10.10, P<0.001).